Question 156 of 433
What is new in 2026?
The short answer
A daily pill and a more powerful injection.
In April 2026 the FDA approved orforglipron, sold as Foundayo, a once-daily GLP-1 pill that needs no special timing around food. Average weight loss in its main trial was about 12 percent at the highest dose over 72 weeks. It is less potent than the injections but far easier to make and distribute, which matters for cost and access.
In 2026, late-stage trials of retatrutide, a weekly injection that acts on three hormones, reported average weight loss of about 28 percent at 80 weeks at the highest dose in people without diabetes, and about 21 to 23 percent in people with heart disease. Its heart-safety data are still incomplete, and the company expects to file for approval in early 2027. It is not legally available, whatever a website tells you.
“This book is for education. It is not medical advice, and reading it does not make you my patient or create a doctor-patient relationship.” From the book’s medical disclaimer. Full disclaimer
HUMAN TRIAL / REGULATORY — Indicated adults: orforglipron approval and weight loss; retatrutide remains investigational.Evidence grade (draft mapping)RRegulatory statusPart 11, Q156 · Sources: R14
Sources cited
- R14 US Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program: Foundayo (orforglipron). April 1, 2026. Link pending verification
From Longevity Unmasked by Afshine Ash Emrani, MD, FACC. Medical disclaimer. This book is for education. It is not medical advice, and reading it does not make you my patient or create a doctor-patient relationship. Nothing here is meant to diagnose, treat, cure, or prevent any disease. Medicine is personal: a test, drug, supplement, or exercise plan that helps one person can harm another. Do not start, stop, or change any medication or treatment because of something you read in these pages. Talk with a licensed clinician who knows your history first. If you think you are having a medical emergency, call 911. The author disclaims responsibility for any loss or harm arising from use of the information in this book.